Business Standard

Lupin gets EIR from USFDA for its manufacturing plant in Nagpur

The company's shares surged 4.14% to Rs 820.40 after they received the inspection report (EIR) from the US drug regulator

lupin
Premium

The US health regulator issues an EIR to a company when an inspection is satisfactorily closed.

BS Web TeamAgencies
Pharma major Lupin has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its manufacturing plant in Nagpur on Monday.

The US health regulator issues an EIR to a company when an inspection is satisfactorily closed.

The health regulator had inspected the company's Nagpur manufacturing facility between January 6 and January 10, 2020, Lupin Ltd said in a statement.


"We are very happy to have received the EIR for our Nagpur facility, our largest and most advanced oral solid

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in